SAR161271

SAR161271 is an investigational insulin receptor agonist developed by Sanofi for the treatment of type 1 diabetes mellitus. It is a peptide-based drug designed to mimic or enhance the action of endogenous insulin by activating the insulin receptor (INSR). Clinical studies evaluated multiple formulations of SAR161271, including versions with and without added zinc, in both healthy subjects and patients with type 1 diabetes. The drug was administered subcutaneously and assessed for safety, pharmacokinetics, and pharmacodynamics using euglycemic glucose clamp techniques. While it demonstrated some activity in reducing C-peptide concentrations (indicating suppression of endogenous insulin release), it did not achieve consistent blood glucose control comparable to standard therapy (insulin glargine) across all tested doses or formulations. Development was ultimately discontinued after phase 2 trials due to insufficient efficacy[1][3][7].